Works matching Hormone receptor positive breast cancer

Results: 4101
    1
    2
    3
    4
    5
    6
    7
    8

    TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.

    Published in:
    2020
    By:
    • Vaklavas, Christos;
    • Roberts, Brian S.;
    • Varley, Katherine E.;
    • Lin, Nancy U.;
    • Liu, Minetta C.;
    • Rugo, Hope S.;
    • Puhalla, Shannon;
    • Nanda, Rita;
    • Storniolo, Anna Maria;
    • Carey, Lisa A.;
    • Saleh, Mansoor N.;
    • Li, Yufeng;
    • Delossantos, Jennifer F.;
    • Grizzle, William E.;
    • LoBuglio, Albert F.;
    • Myers, Richard M.;
    • Forero-Torres, Andres;
    • Translational Breast Cancer Research Consortium (TBCRC)
    Publication type:
    journal article
    9
    10
    11
    12

    Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.

    Published in:
    2022
    By:
    • Ozaki, Yukinori;
    • Aoyama, Yosuke;
    • Masuda, Jun;
    • Inagaki, Lina;
    • Kawai, Saori;
    • Shibayama, Tomoko;
    • Maeda, Tetsuyo;
    • Kurata, Mami;
    • Yoshida, Kazuyo;
    • Saeki, Sumito;
    • Hosonaga, Mari;
    • Fukada, Ippei;
    • Hara, Fumikata;
    • Kobayashi, Takayuki;
    • Kobayashi, Kokoro;
    • Miyake, Satoshi;
    • Takano, Toshimi;
    • Ueno, Takayuki;
    • Ohno, Shinji
    Publication type:
    journal article
    13
    14
    15
    16
    17
    18
    19

    Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214.

    Published in:
    Cancers, 2021, v. 13, n. 17, p. 4399, doi. 10.3390/cancers13174399
    By:
    • Masuda, Norikazu;
    • Yoshinami, Tetsuhiro;
    • Ikeda, Masahiko;
    • Mizutani, Makiko;
    • Yamaguchi, Miki;
    • Komoike, Yoshifumi;
    • Takashima, Tsutomu;
    • Yoshidome, Katsuhide;
    • Tsurutani, Junji;
    • Iwamoto, Mitsuhiko;
    • Fujisawa, Fumie;
    • Yasojima, Hiroyuki;
    • Yamamura, Jun;
    • Morishima, Hirotaka;
    • Aki, Fuminori;
    • Yamada, Tomomi;
    • Morita, Satoshi;
    • Nakayama, Takahiro
    Publication type:
    Article
    20
    21
    22
    23
    24
    25

    Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer.

    Published in:
    Current Oncology, 2023, v. 30, n. 7, p. 6097, doi. 10.3390/curroncol30070454
    By:
    • Alvarado-Miranda, Alberto;
    • Lara-Medina, Fernando Ulises;
    • Muñoz-Montaño, Wendy R.;
    • Zinser-Sierra, Juan W.;
    • Galeana, Paula Anel Cabrera;
    • Garza, Cynthia Villarreal;
    • Sanchez Benitez, Daniel;
    • Limón Rodríguez, Jesús Alberto;
    • Arce Salinas, Claudia Haydee;
    • Guijosa, Alberto;
    • Arrieta, Oscar
    Publication type:
    Article
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43

    High tumour-infiltrating lymphocytes correlate with distinct gene expression profile and favourable survival in single hormone receptor-positive breast cancer.

    Published in:
    Contemporary Oncology / Współczesna Onkologia, 2024, v. 28, n. 1, p. 75, doi. 10.5114/wo.2024.139375
    By:
    • Ciarka, Aleksandra;
    • Kunc, Michał;
    • Popęda, Marta;
    • Łacko, Aleksandra;
    • Radecka, Barbara;
    • Braun, Marcin;
    • Pikiel, Joanna;
    • Litwiniuk, Maria;
    • Pogoda, Katarzyna;
    • Iżycka-Świeszewska, Ewa;
    • Zeller, Anna;
    • Niemira, Magdalena;
    • Pęksa, Rafał;
    • Biernat, Wojciech;
    • Senkus, Elżbieta
    Publication type:
    Article
    44
    45

    The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer.

    Published in:
    JNCI Cancer Spectrum, 2023, v. 7, n. 6, p. 1, doi. 10.1093/jncics/pkad092
    By:
    • Lammers, Senna W M;
    • Geurts, Sandra M E;
    • Hellemond, Irene E G van;
    • Swinkels, Astrid C P;
    • Smorenburg, Carolien H;
    • Sangen, Maurice J C van der;
    • Kroep, Judith R;
    • Graaf, Hiltje de;
    • Honkoop, Aafke H;
    • Erdkamp, Frans L G;
    • Roos, Wilfred K de;
    • Linn, Sabine C;
    • Imholz, Alexander L T;
    • Smidt, Marjolein L;
    • Vriens, Ingeborg J H;
    • Tjan-Heijnen, Vivianne C G
    Publication type:
    Article
    46
    47
    48
    49

    Adding Anti-HER2 Therapy to Neoadjuvant Endocrine Therapy Seems Effective in Hormone Receptor and HER2 Positive Breast Cancer Patients Unfit for Chemotherapy: A Nationwide Population-Based Cohort Study.

    Published in:
    Cancers, 2024, v. 16, n. 24, p. 4188, doi. 10.3390/cancers16244188
    By:
    • de Bruijn, Anne;
    • Schipper, Robert-Jan;
    • Voogd, Adri C.;
    • Pullens, Marleen J. J.;
    • Bloemen, Johanne G.;
    • de Munck, Linda;
    • van Riet, Yvonne E.;
    • Siesling, Sabine;
    • Vriens, Birgit E. P.;
    • Nieuwenhuijzen, Grard A. P.
    Publication type:
    Article
    50